SOUTH SAN FRANCISCO, Calif., March 31 /PRNewswire-FirstCall/ -- Exelixis, Inc. announced today that data from clinical trials of the company's investigational compounds XL647, XL184, XL765 and XL880 will be presented at the 2008 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held from May 30 to June 3, 2008 in Chicago, Illinois. The clinical trial data will be described in two oral presentations (XL184 and XL765), two poster presentations and discussions (XL647), and three poster presentations (XL647 and XL880).
About Exelixis
Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb Company, Genentech, Wyeth Pharmaceuticals and Daiichi-Sankyo. For more information, please visit the company's web site at http://www.exelixis.com.
Exelixis and the Exelixis logo are registered U.S. trademarks.
CONTACT: Charles Butler, Senior Director, Corporate Communications &
Investor Relations, +1-650-837-7277, cbutler@exelixis.com, or Soleil
Harrison, Senior Manager, Corporate Communications, +1-650-837-7012,
sharriso@exelixis.com, both of Exelixis, Inc.
Web site: http://www.exelixis.com/
